Actively Recruiting
Phase III Study of S086 Tablets Compared to Sacubitril Valsartan Sodium for Treating Chronic Heart Failure with Reduced Ejection Fraction
Led by Shenzhen People's Hospital · Updated on 2022-11-03
5
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, randomized, double-blind phase III trial to evaluate the effectiveness and safety of S086 tablets in patients with chronic heart failure who have reduced ejection fraction HFrEF. This study compares S086 tablets to an active control drug, sacubitril valsartan sodium tablets, to see if S086 is not less effective. The trial is led by Shenzhen Peoples Hospital and aims to provide important information for treating this condition. Participants in the trial receive either S086 tablets in doses of 60mg, 120mg, 180mg, or 240mg or sacubitril valsartan sodium tablets in doses of 50mg or 100mg. The study uses a quadruple-blind design where neither the participants nor the researchers know which treatment is given. The treatments are administered in a parallel controlled manner across multiple centers. The primary evaluation occurs at 28 weeks, focusing on the efficacy comparison between the two drugs. During the study, participants will be monitored closely to assess treatment effects and safety. Researchers will measure heart function and related biomarkers to determine the efficacy of the treatments. Participants will continue their regular heart failure therapy during the trial with stable dosing before enrollment. The study includes detailed eligibility screening and ongoing safety assessments throughout the treatment period until the study ends in 2026.
CONDITIONS
Brief Title
S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
Research Team
J
junbo he
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here